|
1
|
Denny L, de Sanjose S, Mutebi M, Anderson
BO, Kim J, Jeronimo J, Herrero R, Yeates K, Ginsburg O and
Sankaranarayanan R: Interventions to close the divide for women
with breast and cervical cancer between low-income and
middle-income countries and high-income countries. Lancet.
389:861–870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brody JG, Rudel RA, Michels KB, Moysich
KB, Bernstein L, Attfield KR and Gray S: Environmental pollutants,
diet, physical activity, body size, and breast cancer: Where do we
stand in research to identify opportunities for prevention? Cancer.
109:2627–2634. 2017. View Article : Google Scholar
|
|
3
|
Kaiser J: Cholesterol forges link between
obesity and breast cancer. Science. 342:10282013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gage M, Wattendorf D and Henry LR:
Translational advances regarding hereditary breast cancer
syndromes. J Surg Oncol. 105:444–451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anothaisintawee T, Wiratkapun C,
Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J,
Hirunpat S, Woodtichartpreecha P, Boonlikit S, Teerawattananon Y
and Thakkinstian A: Risk factors of breast cancer: A systematic
review and meta-analysis. Asia Pac J Public Health. 25:368–387.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glaser SL, Canchola AJ, Keegan TH, Clarke
CA, Longacre TA and Gulley ML: Variation in risk and outcomes of
Epstein-Barr virus-associated breast cancer by epidemiologic
characteristics and virus detection strategies: An exploratory
study. Cancer Causes Control. 28:273–287. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu H, Zhao C, Adhikari VP, Lu L, Huang J,
Wei Y, Luo Q, Dai W, Wu Y, Li X, et al: The prevalence and
clinicopathological features of breast cancer patients with
hepatitis B virusinfection in China. Oncotarget. 8:18185–18190.
2017.PubMed/NCBI
|
|
8
|
White EA and Munger K: Crowd control: E7
conservation is the key to cancer. Cell. 170:1057–1059. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin W, Duluc D, Joo H and Oh S: Dendritic
cell targeting vaccine for HPV-associated cancer. Cancer Cell
Microenviron. 3:e14822016.PubMed/NCBI
|
|
10
|
Torres-Rueda S, Rulisa S, Burchett HE,
Mivumbi NV and Mounier-Jack S: HPV vaccine introduction in Rwanda:
Impacts on the broader health system. Sex Reprod Healthc. 7:46–51.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Einstein MN, Smith KM, Davis TE, Schmeler
KM, Ferris DG, Savage AH, Gray JE, Stoler MH, Wright TC Jr,
Ferenczy A and Castle PE: Clinical evaluation of the
cartridge-based GeneXpert human papillomavirus assay in women
referred for colposcopy. J Clin Microbiol. 52:2089–2095. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ilahi NE, Anwar S, Noreen M, Hashmi SN and
Murad S: Detection of human papillomavirus-16 DNA in archived
clinical samples of breast and lung cancer patients from North
Pakistan. J Cancer Res Clin Oncol. 142:2497–2502. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Omura Y, Jones MK, Nihrane A, Duvvi H,
Shimotsuura Y and Ohki M: More than 97% of human papilloma virus
type 16 (HPV-16) was found with chrysotile asbestos &
relatively smooth round tumor outline, and less than 3% was found
with HPV-18 and tremolite asbestos & irregular
sawtooth-like zigzag outline in breast cancer tissues in over 500
mammograms of female patients: Their implications in diagnosis,
treatment, and prevention of breast cancer. Acupunct Electrother
Res. 38:211–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tavassoli FA and Devolee P: Worldhealth
organization classification of tumors, pathology and genetics of
the breast and female genital organs. IARC press; 2003
|
|
15
|
Wu KK: Cyclooxygenase 2 induction:
Molecular mechanism and pathophysiologic roles. J Lab Clin Med.
128:242–245. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harris RE, Casto BC and Harris ZM:
Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J
Clin Oncol. 5:677–692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu B, Qu L and Yan S: Cyclooxygenase-2
promotes tumor growth and suppresses tumor immunity. Cancer Cell
Int. 15:1062015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gebhardt BM, Varnell ED and Kaufman HE:
Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex
virus type 1 reactivation. J Ocul Pharmacol Ther. 21:114–120. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee SM, Gai WW, Cheung TK and Peiris JS:
Antiviral effect of a selective COX-2 inhibitor on H5N1 infection
in vitro. Antiviral Res. 91:330–334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin CK, Tseng CK, Chen KH, Wu SH, Liaw CC
and Lee JC: Betulinic acid exerts anti-hepatitis C virus activity
via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2
expression. Br J Pharmacol. 2015. View Article : Google Scholar
|
|
21
|
Zhao Q, Guo J, Wang G, Chu Y and HU X:
Suppression of immune regulatory cells with combined therapy of
celecoxib and sunitinib in renal cell carcinoma. Oncotarget.
8:1668–1677. 2017.PubMed/NCBI
|
|
22
|
Tury S, Becette V, Assayag F, Vacher S,
Benoist C, Kamal M, Marangoni E, Bièche I, Lerebours F and Callens
C: Combination of COX-2 expression and PIK3CA mutation as
prognostic and predictive markers forcelecoxib treatment in breast
cancer. Oncotarget. 7:85124–85141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riva B, De Dominici M, Gnemmi I, Mariani
SA, Minassi A, Minieri V, Salomoni P, Canonico PL, Genazzani AA,
Calabretta B and Condorelli F: Celecoxib inhibits proliferation and
survival of chronic myelogeous leukemia (CML) cells via
AMPK-dependent regulation of β-catenin and mTORC1/2. Oncotarget.
7:81555–81570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Subbaramaiah K and Dannenberg AJ:
Cyclooxygenase-2 transcription is regulated by human papillomavirus
16 E6 and E7 oncoproteins: Evidence of a corepressor/coactivator
exchange. Cancer Res. 3976–3985. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhuang ZH, Tsao SW, Deng W, Wang JD, Xia
HH, He H, Feng HC, Wang LD, Gu Q, Lam SK, et al: Early upregulation
of cyclooxygenase-2 in human papillomavirus type 16 and
telomerase-induced immortalization of human esophageal epithelial
cells. J Gastroenterol Hepatol. 23:1613–1620. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T))method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Friedrichs K, Gluba S, Eidtmann H and
Jonat W: Overexpression of p53 and prognosis in breast cancer.
Cancer. 72:3641–3647. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li N, Ye YP, Zhu HF, et al: The effect and
mechanism of HPV16 E6 and E7 on the invasion of breast cancer.
Chongqing Yixue. 41:2572–2574. 2012.
|
|
29
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou Y, Li J, Ji Y, Ren M, Pang B, Chu M
and Wei L: Inconclusive role of human papillomavirus infection in
breast cancer. Infect Agent Cancer. 10:362016. View Article : Google Scholar
|
|
31
|
Bae JM and Kim EH: Human papillomavirus
infection and risk of breast cancer: A meta-analysis of case
control studies. Infect Agents Cancer. 11:142016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Münger K, Basile JR, Duensing S, Eichten
A, Gonzalez SL, Grace M and Zacny VL: Biological activities and
molecular targets of the human papillomavirus E7 oncoprotein.
Oncogene. 20:7888–7898. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grabowska AK, Kaufmann AM and Riemer AB:
Identification of promiscuous HPV16-derived T helper cell epitopes
for therapeutic HPV vaccine design. Int J Cancer. 136:212–224.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Y, Wang YN, Chen CQ, Zhang J, Qian W,
Dong Y, Liu Z, Zhang X, Wang X, Zhang Z, et al: LSD1 binds to HPV16
E7 and promotes the epithelial-mesenchymal transition in cervical
cancer by demethylating histones at the Vimentin promoter.
Oncotarget. 8:11329–11342. 2017.PubMed/NCBI
|
|
35
|
Organista-Nava J, Gómez-Gómez Y,
Ocadiz-Delgado R, García-Villa E, Bonilla-Delgado J,
Lagunas-Martínez A, Tapia JS, Lambert PF, García-Carrancá A and
Gariglio P: The HPV16 E7 oncoprotein increases the expression of
Oct3/4 and stemness-related genes and augments cell self-renewal.
Virology. 499:230–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu F, Li M, Zhang C, Cui J, Liu J, Li J
and Jiang H: Clinicopathological and prognostic significance of
COX-2 immunohistochemical expression in breast cancer: A
meta-analysis. Oncotarget. 8:6003–6012. 2017.PubMed/NCBI
|
|
37
|
Campillo N, Torres M, Vilaseca A, Nonaka
PN, Gozal D, Roca-Ferrer J, Picado C, Montserrat JM, Farré R,
Navajas D and Almendros I: Role of Cyclooxygenase-2 on intermittent
hypoxia-induced lung tumor Malignancy in a mouse model of sleep
apnea. Sci Rep. 7:446932017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hsu HH, Chen MC, Day CH, Lin YM, Li SY, Tu
CC, Padma VV, Shih HN, Kuo WW and Huang CY: Thymoquinone suppresses
migration of LoVo human colon cancer cells by reducing
prostaglandin E2 induced COX-2 activation. World J Gastroenterol.
23:1171–1179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Howe LR: Inflammation and breast cancer.
Cyclooxygenase/prostaglandin signaling and breast cancer. Breast
Cancer Res. 9:2102007. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shirali S, Barari A, Hosseini SA and
Khodadi E: Effects of six weeks endurance training and aloe vera
supplementation on COX-2 and VEGF levels in mice with breast
cancer. Asian Pac J Cancer Prev. 18:31–36. 2017.PubMed/NCBI
|
|
41
|
Sun J, Liu NB, Zhuang HQ, Zhao LJ, Yuan ZY
and Wang P: Celecoxib-erlotinib combination treatment enhances
radiosensitivity in A549 human lung cancer cell. Cancer Biomark.
19:45–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pridgen WL, Duffy C, Gendreau JF and
Gendreau RM: A famciclovir + celecoxib combination treatment is
safe and efficacious in the treatment of fibromyalgia. J Pain Res.
10:451–460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu B, Yan S, Qu L and Zhu J: Celecoxib
enhances anticancer effect of cisplatin and induces anoikis in
osteosarcoma via PI3K/Akt pathway. Cancer Cell Int. 17:12017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu R, Abramson AL, Shikowitz M, Dannenberg
AJ and Steinberg BM: Epidermal growth factor-induced
cyclooxygenase-2 expression is mediated through
phosphatidylinositol-3 kinase, not mitogen-activated
protein/extracellular signal-regulated kinase kinase, in recurrent
respiratory papillomas. Clin Cancer Res. 11:6155–6161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang A, Jeang J, Cheng K, Cheng T, Yang B,
Wu TC and Hung CF: Current state in the development of candidate
therapeutic HPV vaccines. Expert Rev Vaccines. 15:989–1007. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
DA Costa RMG, Araújo R, Santos JMO,
Fernandes M, Neto T, Sousa H, Ribeiro J, Bastos MMSM, Oliveira PA,
Carmo D, et al: Regulation of miRNA-146a and miRNA-150 levels by
celecoxib in premalignant lesions of K14-HPV16 Mice. Anticancer
Res. 37:2913–2918. 2017.PubMed/NCBI
|
|
47
|
Alshafie GA, Abou-Issa HM, Seibert K and
Harris RE: Chemotherapeutic evaluation of Celecoxib, a
cyclooxygenase-2 inhibitor, in a rat mammarytumor model. Oncol Rep.
7:1377–1381. 2000.PubMed/NCBI
|
